M. A. Macías Islas

Erratum to: A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial

T. Ziemssen, N. Tubridy, J. Frederiksen, 2014, Journal of Neurology.

Biological and nonbiological complex drugs for multiple sclerosis in Latin America: regulations and risk management

Y. Fragoso, A. Carrá, D. Bichuetti, 2015, Expert review of neurotherapeutics.

Assessment and Impact of Cognitive Impairment in Multiple Sclerosis: An Overview

E. Ciampi, M. A. Macías Islas, 2019, Biomedicines.

A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial

T. Ziemssen, N. Tubridy, J. Frederiksen, 2014, Journal of Neurology.

Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study

J. Gámez-Nava, M. A. Macías Islas, C. A. Nava-Valdivia, 2023, International Journal of Molecular Sciences.